Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
That's not a bad start, I wish all shares I bought did that .
I never really understand the pricing on those 5ks , as they are 99% mostly chunks being moved between the two markets I think . A £2.70 inbound maybe just to satisfy an order over here , likewise a £2.78 may not be an actual order , its just like moving stock between two shelves .
Its a bit opaque , and I'm sure the MM's are making a bit in-between too .
Hi everyone . Just taken a small entry here ( after coming across Destiny on social media just today ) .
Will be another nice fit with my main holding over at Faron Pharmaceuticals .
A bigger Mcap - but also with a P3 ready candidate - and looking to ink deals .
Anyway - good luck all - looking forward to reading up more about this company .
Three new events in the calendar ( Sept- Dec) Investor events .
https://www.faron.com/investors/event-calendar
I had a 1000 yesterday too . Believing my own hype ? Maybe .
Firstly we are lagging behind Nas price . They are pulling us up as demand seems to be coming from that side.
The majority of Faron shares are in sticky hands - be it Timo , BOD ,Pension funds ,EIC, LLS etc . Not a big percentage in PI hands compared to some companies ( especially on AIM) , and certainly not quick buck traders .
The confidence and smell of success coming is building like you say Sophie . I remember saying a good year ago how Markku would now build a team that could push this across the finish line . MLF , Maija , new SAB members .LLS . New CFO in US . They've kept the IP 100% owned - meaning the bigger the prize at the end of negotiations .
Back then we only had about 30 million shares in circulation - so £8.00 equated to a Mcap of about £240m .
Today we have 66 million . So to be at same Mcap we'd only be at £3.60 a share to achieve the same Mcap .
So not big a gap as it would seem at first sight.
At £8 we were nearing the end of a P3 trial - ready to hit the market .
That was for Traumakine ( 100% of value)- and Bex was still preclinical (0%)
Now its the opposite lol
But yes - market is jaded . and the stockmarket is in a major slump too in this sector.
Faron have had so many 'Jam Tomorrow' moments , that the default expectation here is - more dilution .
Whatever the history - we are now back at the sharp end with FDA meeting coming up that could move us into the VIP lane .
Until we hear that news - I guess a Mcap of about £200m is about right .
That P3 trial disaster in 2018 shot Faron down like a stone as the market fully expected the green light and big profits . In 2023 - we aren't hanging on that 'Go Big or Go Bust ' decision . We have cracking data . P2 ready . A steady Mcap - not hyped up on expectation at the moment . Team in place , Sites up and growing . Huge pipeline potential for combi trials all waiting to be announced .
New website - new US PR investor relations . New US CFO . BOD members actively working on partnership and licensing deals.
The company is much bigger - US offices - US CMO . Tie ups with US clinics , big support from the LLS .
Biomarkers /diagnostic tools / dosing etc all worked out .
I don't think Bexmab alone could add a 0 to the SP . A successful Bexcombo P2 with Keytruda sure would though .
Who knows if someone may try to buy Faron - or just partner up in one treatment area - as each of the next trials show results ?
I know what I'd prefer - but at least at this Mcap - I think we are safe from any major collapse ( famous last words )
New updated website up and running today too - https://www.faron.com/
Plenty of detail on BEXMAB , MATINS etc .
Just in time for all those new US investors lol .
Also noticed that the last RNS turned up via GLOBALNEWSWIRE - on loads of US websites - regional ones ( FOX4 etc) if you did a google search . So looks like the new US Investor relations are making sure the Faron story gets seen .
Interesting .
The two stories both on front page of Clinical Trials Arena
https://www.clinicaltrialsarena.com/news/gilead-sciences-discontinues-study-mds/
Gilead Sciences discontinues ENHANCE study of MDS combination therapy
Patients treated with the combined therapy in the trial showed typical adverse events.
https://www.clinicaltrialsarena.com/news/faron-bexmarilimab-bexmab-study/
Faron presents positive data from BEXMAB study for patients with blood cancer
Three out of five patients in the 6mg/kg bexmarilimab and azacitidine doublet cohort showed complete remission of bone marrow blasts.
Maybe we will see some more activity as money now moves towards the logical alternative .
Gilead acquired magrolimab as part of its $4.9 billion acquisition of Forty Seven back in 2020. However, the antibody has had a bumpy ride through the clinic, with a number of trials placed on hold by the FDA last year due to adverse reactions.
The ENHANCE study had randomized over 500 patients with higher-risk MDS to either receive either its anti-CD47 antibody magrolimab in combination with Bristol Myers Squibb’s Vidaza or Vidaza alone. But Gilead announced in a post-market release Friday that it had discontinued the study due to futility after taking a look at the results of a planned analysis. The primary endpoints were complete response and overall survival.
The Phase 1 combi trial for Bex and Pembrolizumab that was being sponsored by San Antonio Texas has been withdrawn .
Reason given - The sponsor notified the PI that a Phase II trial had been allowed to proceed by the FDA.)
So does this mean that P1 trials are not necessary anymore - as we have been given green light to proceed straight to a Phase 2 trial ?
Faron have so much safety and dosing data now .
I don't know if this is that significant , but the Bexcombo trial is stated on the pipeline page as being 'P2 ready' . This trial wasn't called Bexcombo - but perhaps theres no point doubling up on trials is a bigger P2 Bexcombo is going to unveiled soon ? or maybe this trial will re emerge as a P2 ?
Faron haven't spoken much about this planned trial . Hopefully we may get some combo news to put us in the picture soon .
https://classic.clinicaltrials.gov/ct2/show/NCT05171062?term=faron&draw=3&rank=11
Just caught the last bit of the update -
Asked about how many patients they are expecting to need before pivotal studies .
Her answer was about 50 patients with accelerated approval .
They are hoping for at least 25% OR , and to add at least 3 months to average life expectancy (5 months in these cases) .
Very low bar - as so far they are far exceeding that ( patient 1 is over 13 months , and others are over 8 months already)
So lets see what FDA say . We are still awaiting news on application for breakthrough status / fast track / orphan drug status , and comment on 'accelerated approval ' .
No questions of funding /partnerships today .
The questions were phone in only , and I think they just wanted to get the info out there , via their new IR company .
They are super excited - reading between the lines , this is exactly what they were hoping for - going into Q3/4 - new sites opening in US , so that will be 8 in total - should get 50 patients without too much trouble .
15 so far - probably others been added - so only need about another 4 patients from each site to complete this stage .
One of the unmentioned bit of news that came today was this new LifeSci group - who seem to be the big dog in in the IPO fundraising circle . At some point - US funds are going to want a slice of this pie , if it keeps heading in this direction .
So we have LLS putting us under their wing , and opening doors , 4 US sites now confirmed , and results coming in that are better than anyone could have hoped for at this stage .
Large percentage of shares in stick hands already - so lets see where we go from here .
Good luck everyone .
I normal get a fair price with mine , recently 250 ish before this rise .
The last few weeks have been sticky as I haven't had an instant quote - they seem to turn off when not much going on .
And even today I can't get a quote - despite thousands of shares going over to the Naz ( 100k volume of shares today)
I think maybe the MMs had loaded up or have ben buying from someone needing to sell and are clearing their stock first , hence the low offer for your shares .
When the dust settles should be orderly again .
LifeSci were hosting the event .
I was watching live but got cut off - hopefully it'll be online later .
2 new US sites coming - YALE and UCL in Q3
MLF went through patient details - all pointing to Bex being the main reason these patients responded - as most of the patients that responded had previously relapsed or failed on the Az treatment.
Pipeline showed the trial splitting into two areas I think into P2 - leading up to approval request .
Q&A was just starting when I got cut off -
No . It may get posted up by Faron later for free ( done before) .
I'm sure it's just a update saying that better data is great- further derisks project etc etc .
Just good that this update seems to be quite newsworthy .
Https://www.redeye.se/research/923704/faron-pharmaceuticals-positive-bexmab-study-update
Anyone else notice that there is a new contact at the bottom of the RNS .
Instead of Investor contact being Yrjö Wichmann at Faron , we now have a new US based company - LifeSci Advisors.
They specialise in cross over financing - and have case studies of doing just that for companies like Faron .
Eg - ABIVAX - This process ultimately led to two oversubscribed cross-over financings resulting in an uptick in the stock. Abivax was originally trading at EUR 7.63 on September 1st before their first cross-over financing of EUR 49.2 million and is now trading at EUR 16.2 after their recent deal in February of EUR 130 million, more than 2x the original trading price.
So it appears we may now be being guided and promoted to a much wider and influential investor base .
https://www.lifesciadvisors.com/about-us/
In the newspaper today in Finland -
Faron from Turku is applying for a marketing license for its cancer drug on the US market - could bring help to malignant blood cancers
https://www.ts.fi/uutiset/6053689?utm_medium=Social&utm_source=Twitter#Echobox=1689749120
You'd assume a partnership well before BLA , as it gives Faron the funding , and gives the Partner an early entry price , and more say on future combo direction .
My money has always been on BMS since Bexmab announcement , but who knows .
Either way - Naz is up 13% with good volume - so the market sees this a very positive
Webcast at 1.30pm today -
https://viavid.webcasts.com/starthere.jsp?ei=1625480&tp_key=01bb7cc4d7
Also we have a conference call and webcast - today - so they are getting this out quick .
Looks like things are moving at a faster pace since opening up the US sites - results good enough to get FDA approval for market access ?
I believe Faron think so .